ライフサイエンスコーパス: antifungal

1 makes the former very promising as a natural antifungal.

2 tentially a powerful alternative to standard antifungals.

3 . albicans lost dominance in the presence of antifungals.

4 development of more efficient broad-spectrum antifungals.

5 P5218 to be only a secondary target of azole antifungals.

6 resent a potential target for developing new antifungals.

7 se 2 is crucial for the development of novel antifungals.

8 m of action distinct from currently marketed antifungals.

9 as antitumor agents, immunosuppressants and antifungals.

10 lobosa CYP51 was strongly inhibited by azole antifungals (0.15 to 0.35 muM).

11 ibacterial, 172 antiviral, 105 anti-HIV, 959 antifungal, 80 antiparasitic and 185 anticancer peptides

12 and the purified compound showed significant antifungal activities against the potential saprobic com

13 ethiodide salt of liriodenine, mediate their antifungal activities by disrupting mitochondrial iron-s

14 The antifungal activities of novel 2,3-unsaturated and 2,3-d

15 (CDs) on the solubility, photostability and antifungal activities of some phenylpropanoids (PPs) wer

16 have been tested for their antibacterial and antifungal activities.

17 istration, and the end points used to assess antifungal activity affect the interpretation of data fr

18 synthetic steps, respectively, and they show antifungal activity against a wide range of clinical fun

19 l-sn-glycero-3-phosphocholine exhibited good antifungal activity against Candida albicans with MIC of

20 y of macrocyclic amidinoureas showing potent antifungal activity against Candida spp.

21 tides His(2-Ar)-Trp-His(2-Ar) exhibit potent antifungal activity against Cryptococcus neoformans with

22 It exhibits broad-spectrum antifungal activity against filamentous fungi at submicr

23 -DAPG derivatives, MP4 exhibited much higher antifungal activity against Penicillium digitatum and P.

24 sence of alphaXbeta2 resulted in the loss of antifungal activity by tissue Mvarphi and inhibited the

25 cases, the mechanism that accounts for their antifungal activity has not been fully elucidated.

26 Compound 2 also exhibits nanomolar antifungal activity in synergy with amphotericin B.

27 NSC319726 (a thiosemicarbazone) had broad antifungal activity in the range of 0.1-2.0 microg/ml an

28 trations in dHL-60 cells and increases their antifungal activity in vitro and in vivo.

29 compared to the control (P < 0.05), and the antifungal activity increased as the incorporation of th

30 ans However, the molecular mechanism of this antifungal activity is unknown.

31 udy was to recover and evaluate in vitro the antifungal activity of bioactive compounds of tarbush Fl

32 We studied the biosynthesis, occurrence, and antifungal activity of flavan-3-ols in black poplar (Pop

33 Botrytis cinerea, were chosen to examine the antifungal activity of free and encapsulated PPs.

34 This study aimed to investigate the antifungal activity of liposomal systems containing Spir

35 embrane permeabilization is required for the antifungal activity of MtDef4 against F. graminearum but

36 Herein, we report the synthesis and antifungal activity of novel alkylated piperazines and a

37 The functional capacity and antifungal activity of these cells were assessed in vitr

38 the cytoplasm of these fungi and exerts its antifungal activity on intracellular targets.

39 spectroscopy (FT-IR), sorption isotherms and antifungal activity were evaluated for the characterizat

40 ediated neutrophil and inflammatory monocyte antifungal activity, because lung GM-CSFRbeta(-/-) leuko

41 Encapsulated PPs, despite their reduced antifungal activity, could be helpful to solve drawbacks

42 defensin that exhibits potent broad-spectrum antifungal activity, recruits multiple membrane phosphol

43 em with potent antibacterial, antiviral, and antifungal activity.

44 ntifungals, and only flucytosine showed poor antifungal activity.

45 osed, off-patent compound that has potential antifungal activity.

46 also protects macrophages and augments their antifungal activity.

47 zole is a novel triazole with broad-spectrum antifungal activity.

48 rtant natural product with antibacterial and antifungal activity.

49 ited States, Optisol-GS, does not contain an antifungal additive.

50 ssion, the route of infection, the timing of antifungal administration, and the end points used to as

51 ro antifungal susceptibility pattern of nine antifungals against a selected group of isolates.

52 (ISAV) is a novel, broad-spectrum, triazole antifungal agent (IV and by mouth [PO]) developed for th

53 also identified the approved small-molecule antifungal agent ciclopirox as a novel pan-histone demet

54 ility that MtDef5 might be useful as a novel antifungal agent in transgenic crops.

55 gs demonstrate that EntV has potential as an antifungal agent that targets virulence rather than viab

56 ME1111 is a novel small molecule antifungal agent under development for the topical treat

57 d to be less hemolytic than the FDA-approved antifungal agent voriconazole (VOR).

58 cycles exemplified by the methylation of the antifungal agent voriconazole.

59 Breakpoints are used to predict whether an antifungal agent will be clinically effective against a

60 ich no resistance could be identified and an antifungal agent with activity against diverse fungal pa

61 ylaxis, consensus on the strategy, choice of antifungal agent(s), route of administration, and durati

62 sceptibility to azoles, the most widely used antifungal agent.

63 The combination of antifungal agents (cinnamon bark oil, zinc gluconate and

64 e new 2,3-dideoxyglucosides can be useful as antifungal agents and condiments in foods.

65 an important public health concern, and new antifungal agents are highly desirable.

66 Clinical Question: Are antifungal agents associated with lower rates of mortali

67 Drugs targeting calcineurin are potent antifungal agents but also perturb human immunity thereb

68 m temperature incubation and the addition of antifungal agents decreased growth of Candida species in

69 A limited number of antifungal agents from only a few drug classes are avail

70 The combination of antifungal agents in the emulsions has demonstrated to b

71 Its resistance to certain antifungal agents makes it difficult to treat, especiall

72 rise of fungi that are resistant to existing antifungal agents poses a substantial threat to human he

73 There is significant clinical need for new antifungal agents to manage infections with pathogenic s

74 linical efficacy and toxicity of the various antifungal agents used to prevent infection, and offers

75 Antifungal agents were not associated with obesity (OR =

76 The in vitro assays of free antifungal agents were performed against five fungal str

77 There is an important medical need for new antifungal agents with novel mechanisms of action to tre

78 tic route a promising target for herbicides, antifungal agents, and antibiotics.

79 sive strategies, dosing, durations of use of antifungal agents, and definitions of invasive infection

80 of kanamycin A, show very strong activity as antifungal agents.

81 deal candidates for the development of novel antifungal agents.

82 s of several synthetic and naturally derived antifungal agents.

83 esulted in an increased demand for new azole antifungal agents.

84 munity, underscoring the urgent need for new antifungal agents.

85 med biofilms, which are resistant to current antifungal agents.

86 s is intimately dependent on the efficacy of antifungal agents; however, fungi that are resistant to

87 ignaling and potentiates the activity of the antifungals amphotericin B and micafungin.

88 ITA led to a molecule (CBR-096-4) devoid of antifungal and human cytochrome P450 inhibitory activity

89 eptaibiotic family that shows antibacterial, antifungal and nematicidal activities.

90 A. fumigatus sensitive to the azole class of antifungals and a strain displaying an azole-resistant p

91 rol 14alpha-demethylase (the target of azole antifungals) and a putative fatty acid metabolism protei

92 amilies of clinically important antibiotics, antifungals, and anticancer agents are actually present

93 s tested were susceptible to the majority of antifungals, and only flucytosine showed poor antifungal

94 ion to statins, our screen found that SERMs, antifungals, and several antipsychotic medications reduc

95 ral products with significant antibacterial, antifungal, antiviral, antiparasitic, antitumour, anti-i

96 h intravaginal formulations of topical azole antifungals are first-line treatment for pregnant women,

97 se 1 clinical trials, offering hope that the antifungal armamentarium can be expanded to include a cl

98 es the acquisition of resistance to multiple antifungals, at least partially explaining the elevated

99 The antifungal azoles, posaconazole, itraconazole, and ketoc

100 ly named ROA1), increases resistance against antifungal azoles, which was attributed to an altered me

101 s were all susceptible in vitro to the azole antifungals, but had elevated MICs with caspofungin.

102 The echinocandin antifungal caspofungin inhibits synthesis of cell wall b

103 Candida interaction that might change during antifungal chemotherapy and affect innate immune activat

104 7% to echinocandins; 41% were resistant to 2 antifungal classes and 4% were resistant to 3 classes.

105 6 microg/mL-greater potency than the leading antifungal classes.

106 The administration of antifungal combination therapy had no apparent impact on

107 For many fungus-antifungal combinations, these data might never be avail

108 h-crosslinked suspension was loaded with the antifungal compound, trans-2-hexenal, and coated with th

109 nd biological evaluation of a novel class of antifungal compounds called antibody-recruiting molecule

110 sible natural alternative of antioxidant and antifungal compounds for use against postharvest fruit f

111 In a survey of antifungal compounds from these bacteria, we discovered

112 entification of this pathway as a target for antifungal compounds has potential applications in the d

113 The lack of new antifungal compounds with unique mechanisms of action is

114 and Th2 immunity and an important element of antifungal defenses against cryptococcal infection and C

115 indicate that catechin and PAs are effective antifungal defenses in poplar against foliar rust infect

116 ation but also to proper recognition by this antifungal defensin.

117 Combined analysis showed that preventive antifungal did not decrease mortality (risk ratio, 0.88;

118 Thus, antifungal disk diffusion directly from blood culture bo

119 Antifungal drug development lags far behind in compariso

120 ngal pathogens and are promising targets for antifungal drug discovery because their domain compositi

121 a novel class of drug, the orotomides, is an antifungal drug in clinical development that demonstrate

122 y hepatic stellate cells that identified the antifungal drug itraconazole (ITA) as an inhibitor of MF

123 evolving in parallel in the presence of the antifungal drug nystatin are frequently incompatible wit

124 By tackling antifungal drug resistance as an evolutionary problem, t

125 current knowledge of the mechanisms by which antifungal drug resistance evolves in experimental popul

126 erstand the molecular mechanisms that govern antifungal drug resistance.

127 regulation, and uncover circuitry governing antifungal drug resistance.Cas5 is a transcriptional reg

128 therapeutic strategy and identify Bdf1 as an antifungal drug target that can be selectively inhibited

129 and identifies potential anticryptococcal or antifungal drug targets.

130 of virulence, host-pathogen interactions and antifungal drug therapies in both the clinic and agricul

131 may influence the management of patients on antifungal drug therapy.

132 lts support the development of this class of antifungal drug to treat invasive candidiasis.

133 it was applied in a concise synthesis of the antifungal drug Tolciclate.

134 39 NAIMI episodes, the MIC of the first-line antifungal drug was the most important predictor of ther

135 ucomatous conditions, while voriconazole, an antifungal drug, is retinotoxic.

136 itraconazole, a triazole that is used as an antifungal drug.

137 s associated with identifying broad-spectrum antifungal drugs and highlight novel targets that could

138 Only a few classes of antifungal drugs are available, so the emergence of resi

139 ts because of toxicity and resistance to the antifungal drugs currently in use.

140 h encodes the target of the immunosuppresive antifungal drugs FK506 and rapamycin.

141 New classes of antifungal drugs have only been partly successful in imp

142 to recapitulate the exacerbating effects of antifungal drugs on allergic airway disease.

143 A survey of azole antifungal drugs showed that CYP126A1 is inhibited stron

144 ic activity of C. albicans CYP51 by clinical antifungal drugs that are used systemically (fluconazole

145 The echinocandins are relatively new antifungal drugs that represent, together with the older

146 Additionally, antifungal drugs, including amphotericin B, liposomal am

147 y high mortality despite the availability of antifungal drugs.

148 athways commonly targeted by clinically used antifungal drugs.

149 uced by echinocandins, a front-line class of antifungal drugs.

150 itro antifungal susceptibility against eight antifungal drugs.

151 dulates cell cycle dynamics and responses to antifungal drugs.

152 These beta1 integrins control distinct antifungal effector functions in response to either fung

153 tic basis to explain how matrix controls the antifungal effector functions of neutrophils under condi

154 AgBr/NPVP conferred strong and long-lasting antifungal effects against Candida albicans to the PMMA

155 This study evaluated the antifungal effects on Candida albicans ATCC90028, the cy

156 es to demonstrate this technology, targeting antifungal efflux and biofilm adhesion factors.

157 -AFST assay performed at 3 h of the in vitro antifungal exposure failed to detect C. glabrata isolate

158 l placebo; all participants received topical antifungal eyedrops.

159 y relevant concentrations of 3 commonly used antifungals: fluconazole, caspofungin, and amphotericin

160 ne crucial to these cells' antibacterial and antifungal function.

161 d fungal phagocytosis, as well augmented the antifungal functions by macrophages.

162 ohorts and provides an overview of mammalian antifungal host defenses that show promise for informing

163 be a fundamental process in inflammation and antifungal immune response.

164 hways that drive T cell responses regulating antifungal immunity are incompletely understood.

165 against fungal infection, but their roles in antifungal immunity have not been thoroughly investigate

166 ere we found that JNK1 activation suppresses antifungal immunity in mice.

167 results indicate a direct role for Gal-3 in antifungal immunity whereby this molecule affects the ou

168 ignaling pathways are key activators of host antifungal immunity, little is known about the mechanism

169 TH1 and TH17 cells compromise antiviral and antifungal immunity, respectively, explaining the infect

170 receptor (MR) influences the development of antifungal immunity.

171 antifungals in all patients and intravitreal antifungals in 9 eyes.

172 Initial treatment included systemic antifungals in all patients and intravitreal antifungals

173 nsitizes drug-resistant C. glabrata to azole antifungals in vitro and in animal models for disseminat

174 f biologically active compounds, such as the antifungal indiacen B and the anti-inflammatory coibacin

175 Intravitreal antifungal injection, pars plana vitrectomy (PPV).

176 ls and strategies that allow targeted use of antifungals is essential to preserve drug effectiveness.

177 Long-term use of systemic antifungals is not optimal due to emerging evidence of l

178 Every week, articles disclosing new antifungal leads reported as promising starting points f

179 ria alternata, which we treated with topical antifungal medication.

180 cal excision alone while 6 were treated with antifungal medications.

181 t and distribution of low-cost, high-quality antifungal medicines; and concomitant integration of fun

182 des (HDP), we have identified several active antifungal molecules, which also exhibited potent activi

183 CR3 serves as a master regulator during the antifungal neutrophil response, controlling the affinity

184 elvamicin resembles the clinically important antifungals nystatin A1 and amphotericin B, but it has s

185 , and caspofungin, likely through increasing antifungal penetration of hyphae.

186 Unlike the antifungal peptide histatin 5, it did not require energy

187 cteria, we discovered selvamicin, an unusual antifungal polyene macrolide, in bacterial isolates from

188 Hippolachnin A (1) is an antifungal polyketide that bristles with ethyl groups mo

189 eukocytes loaded ex vivo with the lipophilic antifungal posaconazole could improve delivery of antifu

190 h significantly enhanced the activity of the antifungals posaconazole, amphotericin B, and caspofungi

191 of this study was to identify the impact of antifungal prevention in critically ill immunocompetent

192 Antifungal prevention of systemic candidiasis in immunoc

193 d dental resins with strong and long-lasting antifungal properties are critical for the prevention of

194 antiseptic, and especially antibacterial and antifungal properties have been shown.

195 Free PPs revealed remarkable antifungal properties with isoeugenol showing the lowest

196 ssesses potent antimicrobial, antitumor, and antifungal properties.

197 ; which showed good antibacterial as well as antifungal properties.

198 inib in patients receiving concomitant azole antifungal prophylaxis and gemtuzumab ozogamicin with th

199 rly detection of subclinical disease and how antifungal prophylaxis impacts assay performance.

200 ly available data evaluating the efficacy of antifungal prophylaxis strategies is limited by a lack o

201 Although most lung transplant centers use antifungal prophylaxis, consensus on the strategy, choic

202 The antifungal protein partially purified from the apoplasti

203 E. festucae produces a secreted antifungal protein that is highly expressed in the infec

204 port the characterization of the E. festucae antifungal protein, designated Efe-AfpA.

205 ichloe spp. do not have a gene for a similar antifungal protein.

206 ich might become viable adjuncts to existing antifungal regimens.

207 ng degrees of expression stochasticity of an antifungal resistance gene.

208 otential of our assay for rapid detection of antifungal resistance, although the MS-AFST assay perfor

209 parents to analyze the mutational basis for antifungal resistance.

210 Treatment options are limited, due to antifungal resistance.

211 Diagnosis of antifungal-resistant Candida infections is critical to t

212 ric oxide production eliminated the enhanced antifungal response found in JNK1-deficient mice.

213 uired for induction of a proinflammatory and antifungal response.

214 often have prolonged or repeated exposure to antifungals resulting in either the well-documented sele

215 ogenic lines, further support the endogenous antifungal role of selinene-derived metabolites.

216 resistance either emerges in response to an antifungal selection pressure in the individual patient

217 The first synthesis of antifungal sesquiterpene quinol dasyscyphin E was achiev

218 Additionally, an antifungal (Sinefungin) and several anti-viral drugs (e.

219 uction of unnecessary use of antifungals via antifungal stewardship is critical to limit multidrug re

220 An effective antifungal stewardship programme is essential to control

221 isk groups may more efficiently target early antifungal strategies and utilization of newer diagnosti

222 Improved diagnostics and antifungal strategies are therefore urgently required.

223 therefore, been postulated as an adjunctive antifungal strategy.

224 sponding populations to gradually increasing antifungal stress.

225 toma has no acceptable treatment at present; antifungals such as ketoconazole and itraconazole have b

226 ls received no C albicans inoculation and no antifungal supplementation (negative controls).

227 micin and streptomycin (GS) with and without antifungal supplementation.

228 ent between the results of direct testing of antifungal susceptibilities from blood culture bottles b

229 nited States and to determine their in vitro antifungal susceptibility against eight antifungal drugs

230 al institution and by obtaining the in vitro antifungal susceptibility pattern of nine antifungals ag

231 DI-ToF mass spectrometry-based assay for the antifungal susceptibility testing (AFST) of the potentia

232 We conducted antifungal susceptibility testing and whole-genome seque

233 Antifungal susceptibility testing has evolved from a res

234 The antifungal susceptibility testing of FLC and penicillin

235 Based on this data, the CLSI Subcommittee on Antifungal Susceptibility Tests approved the susceptibil

236 m the BET family of proteins, as a potential antifungal target in Candida albicans, a major human fun

237 s fortify the case for the Trl1 kinase as an antifungal target.

238 this proteinogenic amino acid as a potential antifungal target.

239 s, which may lead to genotypic or phenotypic antifungal testing in clinical practice.

240 s an important role in triggering protective antifungal Th17 responses.

241 The antifungal that showed the greatest in vitro activity ag

242 and there is a pressing need to develop new antifungal therapeutic agents because of toxicity and re

243 Notably, JNK inhibitors exerted potent antifungal therapeutic effects in both mouse and human c

244 d individuals, posing an urgent need for new antifungal therapeutic strategies.

245 ings establish BET inhibition as a promising antifungal therapeutic strategy and identify Bdf1 as an

246 ntial applications in the development of new antifungal therapies.

247 regulation and potential targeting for novel antifungal therapies.

248 wall provides pathogen-specific targets for antifungal therapy and distinct molecular patterns that

249 nt on Candida BSI prevalence and the cost of antifungal therapy and T2Candida test reagents.

250 nfections, the administration of appropriate antifungal therapy could be accelerated by the timely re

251 ue to the inability to initiate an effective antifungal therapy early in the disease process.

252 hours of delay in initiating the appropriate antifungal therapy following a positive blood culture.

253 Delayed antifungal therapy for invasive candidiasis (IC) contrib

254 l serious fungal infections need appropriate antifungal therapy for successful patient outcome.

255 a weak recommendation to withhold empirical antifungal therapy in IFD low-risk patients with prolong

256 on, which eventually resolves whether or not antifungal therapy is administered, to a variety of pulm

257 Early administration of appropriate antifungal therapy is hampered by the slow turnovers of

258 sentation, ongoing management, and empirical antifungal therapy of pediatric FN were reviewed; the mo

259 Corticosteroid and antifungal therapy perturb this response, resulting in d

260 When systemic antifungal therapy was started empirically at the time o

261 us catheter, and 41% were receiving systemic antifungal therapy when C. auris was isolated.

262 placebo for 6 weeks, along with combination antifungal therapy with amphotericin B and fluconazole.

263 e unit (ICU) patients with sepsis, empirical antifungal therapy, initiated for suspected fungal infec

264 infection is essential to guide appropriate antifungal therapy.

265 predict meningitis, requiring more intensive antifungal therapy.

266 high morbidity and mortality despite optimal antifungal therapy.

267 fungal disease (IFD) is critical for guiding antifungal therapy.

268 ubstantial changes were related to empirical antifungal therapy.

269 ost patients with fungal asthma benefit from antifungal therapy.

270 %) patients had progressive IFD despite this antifungal therapy.

271 nt oral medication is a promising adjunctive antifungal therapy.

272 tification is necessary to guide appropriate antifungal therapy.

273 t, and all received intravitreal or systemic antifungal therapy.

274 es seemed to be lower in patients undergoing antifungal therapy.

275 Impaired delivery of antifungals to hyphae within necrotic lesions is thought

276 ungal posaconazole could improve delivery of antifungals to the sites of established infection and im

277 ly useful for developing diagnostics and new antifungals to treat biofilm-based infections.

278 ixture of three fungi found to expand during antifungal treatment (Aspergillus amstelodami, Epicoccum

279 Bottom Line: Antifungal treatment administered prior to diagnosis of

280 the low response of A. terreus infections to antifungal treatment and could be responsible for its hi

281 Prompt systemic antifungal treatment at the time of skin presentation fo

282 Overall, our data suggest that antifungal treatment favors the growth of specific non-

283 Antifungal treatment in this setting is associated with

284 Antifungal treatment is indicated in almost all patients

285 Antifungal treatment is more complex than treatment for

286 ly diagnosis, dermatologic presentation, and antifungal treatment on outcomes are lacking.

287 We explore current antifungal treatment options and discuss promising strat

288 Antifungal treatment or autoreactive CD4 T cell depletio

289 andida glabratais increasingly refractory to antifungal treatment or prophylaxis and relatedly is inc

290 e costs included those of T2Candida testing, antifungal treatment, and hospital length of stay.

291 ofilms and how these dynamics are altered by antifungal treatment.

292 igh dissemination rates and poor response to antifungal treatment.

293 alis, which are frequently more resistant to antifungal treatment.

294 f randomized controlled trials comparing any antifungal use versus placebo to prevent candidiasis in

295 Drivers are overall antifungal use, subtherapeutic drug levels at sites of i

296 Reduction of unnecessary use of antifungals via antifungal stewardship is critical to li

297 Empiric antibiotics, antivirals, and antifungals were administered in 85.8%, 53.4%, and 7.8%,

298 n DCs A. terreus conidia were protected from antifungals, whereas A. fumigatus conidia were efficient

299 sis require the protracted administration of antifungals, which can result in significant toxicities

300 One of these molecules is a novel antifungal, while several others inhibit a cysteine prot